Approval · Notice of Compliance 33562 · 2024
VIMPAT: Notice of Compliance 33562
Issued July 5, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33562
- Date
- July 5, 2024
- Company
- Ucb Canada IncOakville, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New package labels. Update to package insert.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VIMPAT | Not yet assigned | — |
Medicinal ingredients
- LACOSAMIDE 50 MG per TAB
- LACOSAMIDE 100 MG per TAB
- LACOSAMIDE 150 MG per TAB
- LACOSAMIDE 200 MG per TAB
- LACOSAMIDE 10 MG per ML